$ADPT Adaptive Biotechnologies Corp Insider Trading Week 10/2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adaptive Biotechnologies Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Adaptive Biotechnologies Corp in week 10/2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 10,000 | 63,200 | 45,000 | |
| Mar 12 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 42.54 | 10,000 | 425,400 | 21,604 | 31.6 K to 21.6 K (-31.64 %) |
| Mar 12 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 10,000 | 63,200 | 31,604 | 21.6 K to 31.6 K (+46.29 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 42.38 | 30,268 | 1,282,664 | 12,309,090 | 12.3 M to 12.3 M (-0.25 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.47 | 25,732 | 1,067,037 | 12,339,358 | 12.4 M to 12.3 M (-0.21 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.16 | 34,302 | 1,411,887 | 12,365,090 | 12.4 M to 12.4 M (-0.28 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 40.42 | 215,698 | 8,719,333 | 12,399,392 | 12.6 M to 12.4 M (-1.71 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.62 | 85,911 | 3,575,753 | 12,615,090 | 12.7 M to 12.6 M (-0.68 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 41.21 | 71,194 | 2,933,641 | 12,701,001 | 12.8 M to 12.7 M (-0.56 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 39.97 | 33,600 | 1,343,039 | 12,772,195 | 12.8 M to 12.8 M (-0.26 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 39.22 | 75,000 | 2,941,163 | 12,805,795 | 12.9 M to 12.8 M (-0.58 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 38.22 | 234,295 | 8,954,310 | 12,880,795 | 13.1 M to 12.9 M (-1.79 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 10,000 | 63,200 | 55,000 | |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.79 | 2,890 | 117,883 | 21,064 | 24 K to 21.1 K (-12.06 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.02 | 7,110 | 284,542 | 23,954 | 31.1 K to 24 K (-22.89 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 10,000 | 63,200 | 31,064 | 21.1 K to 31.1 K (+47.47 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 53,000 | |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 44.56 | 2,000 | 89,120 | 0 | 2 K to 0 (-100.00 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 2,000 | 0 to 2 K |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 53,000 | |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 44.56 | 2,000 | 89,120 | 1,504 | 3.5 K to 1.5 K (-57.08 %) |
| Mar 10 2021 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 3,504 | 1.5 K to 3.5 K (+132.98 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | A | 43.68 | 57,234 | 2,499,981 | 57,234 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Grant | A | 0.00 | 22,894 | 0 | 22,894 | 0 to 22.9 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | A | 43.68 | 114,469 | 5,000,006 | 114,469 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Grant | A | 0.00 | 45,788 | 0 | 45,788 | 0 to 45.8 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | A | 43.68 | 171,703 | 7,499,987 | 171,703 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Grant | A | 0.00 | 68,681 | 0 | 69,360 | 679 to 69.4 K (+10,115.02 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | A | 43.68 | 34,341 | 1,500,015 | 34,341 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Grant | A | 0.00 | 13,736 | 0 | 15,036 | 1.3 K to 15 K (+1,056.62 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Option Exercise | A | 43.68 | 22,894 | 1,000,010 | 22,894 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Palaniappan Jyoti | SVP, Diagnostics, i ... | Grant | A | 0.00 | 9,158 | 0 | 9,158 | 0 to 9.2 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ADAMS R MARK | EVP & Chief Operati ... | Option Exercise | A | 43.68 | 51,511 | 2,250,000 | 51,511 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ADAMS R MARK | EVP & Chief Operati ... | Grant | A | 0.00 | 20,604 | 0 | 70,604 | 50 K to 70.6 K (+41.21 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | A | 43.68 | 57,234 | 2,499,981 | 57,234 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Grant | A | 0.00 | 22,894 | 0 | 22,894 | 0 to 22.9 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Option Exercise | A | 43.68 | 51,511 | 2,250,000 | 51,511 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Grant | A | 0.00 | 20,604 | 0 | 20,604 | 0 to 20.6 K |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | A | 43.68 | 171,703 | 7,499,987 | 171,703 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Grant | A | 0.00 | 68,681 | 0 | 1,778,461 | 1.7 M to 1.8 M (+4.02 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | A | 43.68 | 51,511 | 2,250,000 | 51,511 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Grant | A | 0.00 | 20,604 | 0 | 21,604 | 1,000 to 21.6 K (+2,060.40 %) |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BOBULSKY SUSAN | SVP, Diagnostics, c ... | Option Exercise | A | 43.68 | 22,894 | 1,000,010 | 22,894 | |
| Mar 08 2021 | ADPT | Adaptive Biotechno ... | BOBULSKY SUSAN | SVP, Diagnostics, c ... | Grant | A | 0.00 | 9,158 | 0 | 9,158 | 0 to 9.2 K |